

## Investigating the impact of FreeStyle Libre personal CGM systems on hypoglycemia<sup>1,\*</sup>

### **OBJECTIVE:**

To assess whether FreeStyle Libre personal CGM systems reduce exposure to hypoglycemia in patients with type 1 diabetes compared with self-monitored blood glucose (SMBG) testing<sup>1,\*</sup>

### **RESEARCH DESIGN & METHODS:**

26 WEEK

multicenter, prospective, non-masked, randomized controlled trial



241

ADULT PATIENTS WITH TYPE 1 DIABETES (>18 YEARS) SPLIT INTO 2 GROUPS:

Intervention group: MDI + CGM (n=121) Control group: MDI + SMBG (n=120)


MDI: multiple daily injections

### **PRIMARY OUTCOME:**

Change in time in hypoglycemia (<70 mg/dL) between baseline and 6 months

Patients with type 1 diabetes using the FreeStyle Libre personal CGM systems experienced:

- A 95-minute reduction over baseline
- Sustained reductions in duration of hypoglycemia<sup>†</sup>



REDUCTION IN OVERALL HYPOGLYCEMIA<sup>‡</sup>

(P<0.0001)







### **SECONDARY OUTCOMES:**

Significant sustained increase in blood glucose testing frequency, exceeding the ADA's glucose monitoring guidelines of testing at least 6-10 times per day<sup>2</sup>

### MONITORING ~3X MORE =

(vs self-monitored blood glucose testing)

T1D MDI patients showed **improved adherence** to glucose monitoring guidelines, which is associated with improved HbA1c<sup>1,\*</sup>

### SERIOUS HYPOGLYCEMIA



### NOCTURNAL HYPOGLYCEMIA



**reduction** of time in nocturnal hypoglycemia (<70 mg/dL from 2300 to 0600 h within 7 h) vs SMBG (*P*<0.0001)<sup>1,\*</sup>

# IMPROVED PATIENT-REPORTED TREATMENT SATISFACTION<sup>1,\*</sup>





If you would like more information about the FreeStyle Libre family of personal CGM systems, please visit **Payer.FreeStyleLibre.us** 



- \* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
- † Through 6-month study period.
- ‡ vs SMBG.
- § Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

**References: 1.** Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." *The Lancet* 10057, no. 388 (September 2016): 2254-2263. DOI: https://doi.org/10.1016/S0140-6736(16)31535-5. **2.** American Diabetes Association. *Diabetes Care*. 2020;43(suppl 1):S77-S88.

### **Indications and Important Safety Information**

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.\(^\text{WARNINGS/LIMITATIONS}\(^\text{T:}\) The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit \(^\text{WW.FreeStyleLibre.us}\) www.FreeStyleLibre.us for detailed indications for use and safety information.

II Please refer to www.FreeStyleLibre.us for the indications and important safety information.

The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. Product images are for illustrative purposes only.

©2020 Abbott. All rights reserved. ADC-23682 v1.0 10/20